JP2004517049A5 - - Google Patents

Download PDF

Info

Publication number
JP2004517049A5
JP2004517049A5 JP2002525102A JP2002525102A JP2004517049A5 JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5 JP 2002525102 A JP2002525102 A JP 2002525102A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5
Authority
JP
Japan
Prior art keywords
solvate
salt
functional derivative
physiologically functional
ylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002525102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/026423 external-priority patent/WO2002020479A1/en
Publication of JP2004517049A publication Critical patent/JP2004517049A/ja
Publication of JP2004517049A5 publication Critical patent/JP2004517049A5/ja
Pending legal-status Critical Current

Links

JP2002525102A 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 Pending JP2004517049A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23005000P 2000-09-01 2000-09-01
PCT/US2001/026423 WO2002020479A1 (en) 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004517049A JP2004517049A (ja) 2004-06-10
JP2004517049A5 true JP2004517049A5 (enExample) 2005-04-07

Family

ID=22863755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002525102A Pending JP2004517049A (ja) 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体

Country Status (5)

Country Link
US (2) US7071217B2 (enExample)
EP (1) EP1339680A1 (enExample)
JP (1) JP2004517049A (enExample)
AU (1) AU2001288374A1 (enExample)
WO (1) WO2002020479A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020479A1 (en) * 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
SI1556083T1 (sl) 2002-10-08 2011-05-31 Rinat Neuroscience Corp Postopki za zdravljenje postoperativne bolečine z dajanjem protitelesa proti živčnemu rastnemu faktorju in sestavki, ki ga vsebujejo
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
AU2003299898B2 (en) 2002-12-24 2010-12-16 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
NZ549990A (en) 2004-04-07 2009-08-28 Rinat Neuroscience Copr Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
WO2006123113A2 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2626375A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
CA2649043C (en) 2006-04-19 2013-09-17 Astellas Pharma Inc. Azolecarboxamide derivative
MX2009000456A (es) 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
CA2711865A1 (en) 2008-01-11 2009-07-16 Astellas Pharma Inc. A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
EP4514998A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
AU2024238259A1 (en) 2023-03-17 2025-08-21 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6269086B1 (en) 1998-02-27 2001-07-31 Legerity, Inc. Arrangement and method for selectable time/frequency division multiplex communication
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6498176B1 (en) 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
WO2002020479A1 (en) * 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds

Similar Documents

Publication Publication Date Title
JP2004517049A5 (enExample)
JP6021805B2 (ja) 腫瘍治療剤
JP2004517087A5 (enExample)
JP2005508337A5 (enExample)
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
RU2008112221A (ru) Соединения ряда изоиндолимидов, их композиции и способы применения
JPWO2020038415A5 (enExample)
JP2005523922A5 (enExample)
JP2005509024A5 (enExample)
JP2006509749A5 (enExample)
JP2005513123A5 (enExample)
JP2014502979A5 (enExample)
JP2010501478A5 (enExample)
AU2011227398A1 (en) Modulators of Hec1 activity and methods therefor
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
JP2020512337A5 (enExample)
JP2008534453A5 (enExample)
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
CN110461837B (zh) 新型吡咯并吡啶衍生物、其制备方法及用途
EP3286179A1 (en) Compositions and methods for inhibiting kinases
RU2004119963A (ru) Ингибиторы вич интегразы
JP2006516626A5 (enExample)
JP2009501745A5 (enExample)
JP2007501284A5 (enExample)
RU2007120710A (ru) Способ лечения рака и/или лейкоза и применяемая в нем фармацевтическая композиция